Conclusion
Owing to the straightforward synthesis and chemical modification, high
target specificity, low toxicity, and broad range of targets, peptides
have become a viable option for treating various diseases. This review
provides an overview of the studies that employ organoids to assess the
effects of peptide candidates, exploring the utility and challenges of
high-throughput screening of peptide using organoids in light of the
experiences from the organoid-based small molecule screens that have
been extensively examined in recent years. Despite the limitations and
difficulties in developing an organoid-based peptide high-throughput
platform, various techniques can be employed to overcome these issues,
including the advancement of organoid technology. Consequently,
organoids will be a captivating and novel preclinical model for
discovering peptide drugs in the future.